KR20070036057A - 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체 - Google Patents

코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체 Download PDF

Info

Publication number
KR20070036057A
KR20070036057A KR1020067025253A KR20067025253A KR20070036057A KR 20070036057 A KR20070036057 A KR 20070036057A KR 1020067025253 A KR1020067025253 A KR 1020067025253A KR 20067025253 A KR20067025253 A KR 20067025253A KR 20070036057 A KR20070036057 A KR 20070036057A
Authority
KR
South Korea
Prior art keywords
leu
val
protein
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067025253A
Other languages
English (en)
Korean (ko)
Inventor
칼-빌헬름 보겔
데이비드 씨. 프리징거
Original Assignee
유니버시티 오브 하와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 하와이 filed Critical 유니버시티 오브 하와이
Publication of KR20070036057A publication Critical patent/KR20070036057A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
KR1020067025253A 2004-04-30 2005-04-29 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체 Ceased KR20070036057A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56706904P 2004-04-30 2004-04-30
US60/567,069 2004-04-30
US65324705P 2005-02-14 2005-02-14
US60/653,247 2005-02-14
US66735205P 2005-03-31 2005-03-31
US60/667,352 2005-03-31

Publications (1)

Publication Number Publication Date
KR20070036057A true KR20070036057A (ko) 2007-04-02

Family

ID=35320733

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067025253A Ceased KR20070036057A (ko) 2004-04-30 2005-04-29 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체

Country Status (9)

Country Link
US (2) US8632780B2 (enExample)
EP (1) EP1755658A4 (enExample)
JP (1) JP2008502323A (enExample)
KR (1) KR20070036057A (enExample)
AU (1) AU2005240096A1 (enExample)
CA (1) CA2565227A1 (enExample)
IL (1) IL178905A0 (enExample)
MX (1) MXPA06012321A (enExample)
WO (1) WO2005107785A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
MXPA06012321A (es) 2004-04-30 2007-04-19 Univ Hawaii Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
JP6488376B2 (ja) * 2014-06-12 2019-03-20 ユニヴァーシティ オブ ハワイUniversity Of Hawaii 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
CN106472354B (zh) * 2016-10-21 2019-05-31 新希望六和饲料股份有限公司 一种成年鸡用饲料盘
CN106472359B (zh) * 2016-10-21 2019-07-26 新希望六和饲料股份有限公司 一种1-3周龄雏鸡用饲料盘

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US5714344A (en) 1993-04-07 1998-02-03 Georgetown University Protease-derivatized CVF
WO1994023024A1 (en) 1993-04-07 1994-10-13 Georgetown University Dna encoding cobra c3, cvf1, and cvf2
DE69533359T2 (de) 1994-09-08 2005-07-28 Imutran Ltd. Veränderte menschliche c3-proteine
US6221657B1 (en) 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
MXPA06012321A (es) 2004-04-30 2007-04-19 Univ Hawaii Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.
US20100179092A1 (en) 2006-11-15 2010-07-15 Fritzinger David C Human complement c3 derivatives with cobra venom factor-like function

Also Published As

Publication number Publication date
AU2005240096A1 (en) 2005-11-17
US20080311132A1 (en) 2008-12-18
EP1755658A2 (en) 2007-02-28
US20080234191A1 (en) 2008-09-25
EP1755658A4 (en) 2008-11-05
IL178905A0 (en) 2007-03-08
US8632780B2 (en) 2014-01-21
WO2005107785A3 (en) 2005-12-15
WO2005107785A2 (en) 2005-11-17
CA2565227A1 (en) 2005-11-17
MXPA06012321A (es) 2007-04-19
JP2008502323A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
JPS63503275A (ja) ファクター8:cの製造方法
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
US20080234191A1 (en) Human complement C3 derivates with cobra venom factor-like function
JP2001524313A (ja) 哺乳類のサイトカイン様ポリペプチド−10
JPH10502527A (ja) TGF−βファミリーの新規な成長/分化因子
KR20170012582A (ko) Alk1 수용체 및 리간드 길항제 및 그의 용도
WO2003029401A2 (en) Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
KR20210014224A (ko) 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 alk1 길항제 기재의 방법 및 조성물
JP2010187691A (ja) 哺乳類のトランスフォーミング増殖因子β−9
JP2002526073A (ja) 新規のヒト生長分化因子のコード配列、そのdna配列によりコードされるポリペプチド、およびこれらの製造方法。
US20030181372A1 (en) Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
KR20020073152A (ko) 보체 활성화의 저해물질, 이들의 제조 및 용도
JP4855627B2 (ja) 医薬用途のためのトロンボモジュリン
Cheng et al. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H
Vogel et al. Cobra venom factor: the unique component of cobra venom that activates the complement system
JP2002540763A (ja) 33個のヒト分泌タンパク質
US20080045699A1 (en) Interleukin-1 Related Gene and Protein
AU769933B2 (en) Angiostatin-binding protein
JP2001515720A (ja) β−デフェンシン
JP2000515001A (ja) ダウンレギュレーション耐性c3コンバターゼ
JPWO1999014325A1 (ja) 新規Fasリガンド誘導体
US20030211991A1 (en) Human sez6 nucleic acids and polypeptides
CA2600749C (en) Dimeric or multimeric microproteins
CN100425695C (zh) 新型人Rab GTP酶,其编码序列及用途
JPH06502541A (ja) フォン・ウィルブランド因子の治療断片

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100415

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110929

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I